Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 186.64

-2.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (11948)	12/1/1997 6:46:00 PM
From: Henry Niman	Read Replies (1) of 32384

Andy, Herre's a few words on PPARs under the "Cardiovascular" section of LGND's on-line Annual Report: Exciting discoveries in the cardiovascular program area have facilitated expansion of Ligand's drug development focus into additional therapeutic areas. Early in 1996, Ligand scientists, in collaboration with scientists from Institute Pasteur de Lille, published new information in the Proceedings of the National Academy of Sciences defining the promoter of the human leptin gene. Patent claims connected with this work have been filed on behalf of Ligand. In addition, the role of the PPAR (peroxisome proliferator-activated receptor) family of IRs in the regulation of key genes in diabetes, obesity and cardiovascular disease has been further elucidated. Discovery progress in both of these areas culminated in the creation of a program targeting metabolic diseases. (see pages 12-15.) The collective use of research information from several different labs at Ligand allows us to expand our discovery efforts and demonstrates the importance of Ligand's scientific critical mass and our ability to achieve synergies across different therapeutic platforms.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next